| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/27/2006 | EP1703910A2 Treatment of aromatase inhibitor therapy-related osteoporosis |
| 09/27/2006 | EP1703907A2 Compositions and methods to treat recurrent medical conditions |
| 09/27/2006 | EP1703902A2 Memantine for the treatment of mild and mild-to-moderate alzheimer's disease |
| 09/27/2006 | EP1624878B1 Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain |
| 09/27/2006 | EP1615638B1 Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy |
| 09/27/2006 | EP1545218A4 Full range nutritional supplements from plant materials and methods for their manufacture |
| 09/27/2006 | EP1486208B1 Use of a novel preventive for infections |
| 09/27/2006 | EP1461062B1 Composition and method for treating chronic allograft rejection |
| 09/27/2006 | EP1450792B1 Benzazole derivatives for the treatment of scleroderma |
| 09/27/2006 | EP1404341B1 Active substance combination for medicamentous therapy of nicotine dependency |
| 09/27/2006 | EP1395590B1 Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists |
| 09/27/2006 | EP1368008B1 Transdermal therapeutic system for the administration of the partial dopamine-d2 agonist aripiprazol |
| 09/27/2006 | EP1322293B1 Modified release formulation |
| 09/27/2006 | EP1303537B1 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 09/27/2006 | EP1246622B1 Novel substituted benzimidazole dosage forms and method of using same |
| 09/27/2006 | EP1123088B1 Sustained-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
| 09/27/2006 | CN1838964A Treatment and prevention of pulmonary conditions |
| 09/27/2006 | CN1838962A Injection of bone marrow-derived cells and medium for angiogenesis |
| 09/27/2006 | CN1838958A Methods of treating COPD and pulmonary hypertension |
| 09/27/2006 | CN1838947A Glycyrrhizin or derivatives thereof for treating or preventing severe acute respiratory syndrome (SARS) |
| 09/27/2006 | CN1836670A Microsphere injection for treating ophthalmopathy |
| 09/27/2006 | CN1836650A Antineoplastic precharging preparation |
| 09/27/2006 | CN1276748C Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 09/26/2006 | US7112666 Von Willebrand Factor (Vwf)-cleaving protease |
| 09/26/2006 | US7112660 Modified cytokine |
| 09/26/2006 | US7112606 Heterocyclic arylsulfonamidobenzylic compounds |
| 09/26/2006 | US7112597 5-(Substituted thiazolylethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 09/26/2006 | US7112586 Substituted diamine derivatives useful as motilin antagonists |
| 09/26/2006 | US7112578 Methods and compositions for treatment of inflammatory disease |
| 09/26/2006 | US7112427 Protein comprising mitogenic kinase activity for identifying modulators of inflammation, apoptosis and cell proliferation; antiproliferative agents |
| 09/26/2006 | US7112426 Human cAMP-dependent protein kinase beta-catalytic subunit |
| 09/26/2006 | US7112415 Method of preparing cell cultures from biological specimens for assaying a response to an agent |
| 09/26/2006 | US7112414 Masp-2, a complement-fixing enzyme, and uses for it |
| 09/26/2006 | US7112412 Binding to prostate specific membrane antigen (PSMA) with a radioactive monoclonal antibody or Fab fragments; detecting and kill the cancer cells; bioassay; radiotherapy |
| 09/26/2006 | CA2470201C Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
| 09/26/2006 | CA2305762C Delayed total release gastrointestinal drug delivery system |
| 09/26/2006 | CA2283464C Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 09/26/2006 | CA2254953C Therapies for chronic renal failure |
| 09/21/2006 | WO2006099591A1 Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
| 09/21/2006 | WO2006099480A2 Stress proteins and peptides and methods of use thereof |
| 09/21/2006 | WO2006099374A1 Antiviral compositions and methods of use |
| 09/21/2006 | WO2006099095A2 Ribosome inhibitors as inhibitors of tyrosyl-dna-phosphodiesterase |
| 09/21/2006 | WO2006098520A1 Screening method |
| 09/21/2006 | WO2006098394A1 Method for inhibiting lipid absorption and lipid absorption inhibitor |
| 09/21/2006 | WO2006098314A1 Novel sugar uptake activator and method for screening the same |
| 09/21/2006 | WO2006098304A1 Novel secretory protein derived from pituitary cell and use of the same |
| 09/21/2006 | WO2006098292A1 Therapeutic agent for ophthalmic disease |
| 09/21/2006 | WO2006046734A3 Novel aminopyridine derivatives having selective aurora-a inhibitory effect |
| 09/21/2006 | WO2006002422A9 Compounds for immunopotentiation |
| 09/21/2006 | WO2005055932A3 Therapeutic combinations and methods including irm compounds |
| 09/21/2006 | US20060212109 Delivery of therapeutic capable agents |
| 09/21/2006 | US20060211748 Sulphydryl compounds in combination with sulpha compounds |
| 09/21/2006 | US20060211688 Vehicle for topical delivery of anti-inflammatory compounds |
| 09/21/2006 | US20060211674 Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor |
| 09/21/2006 | US20060211664 Method for treating erectile dysfunction and increasing libido in men |
| 09/21/2006 | US20060211661 24 hydroxyvitamin d, analogs and uses thereof |
| 09/21/2006 | US20060211654 Pharmaceutical Compositions of Cholesteryl Ester Transfer Protein Inhibitor |
| 09/21/2006 | US20060211646 Formulations with anti-tumour action |
| 09/21/2006 | US20060211639 Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| 09/21/2006 | US20060211622 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof |
| 09/21/2006 | US20060211621 Combined use of factor VII polypeptides and factor IX polypeptides |
| 09/21/2006 | US20060211613 Administering parathyroid hormone and bone resorption inhibitor; bone disorders |
| 09/21/2006 | US20060211602 Use of alanyl aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 09/21/2006 | US20060211150 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211149 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211143 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211142 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance |
| 09/21/2006 | US20060211090 Human cDNAs and proteins and uses thereof |
| 09/21/2006 | US20060211058 Diagnosis and treatment of malignant neoplasms |
| 09/21/2006 | US20060211042 Methods of identifying modulators of cellular glycosylation using gtrap3-18 |
| 09/21/2006 | US20060211025 Molecular signatures of commonly fatal carcinomas |
| 09/21/2006 | US20060211013 Method for sorting antifungal molecules acting on the glucanosyltransferase activity |
| 09/21/2006 | US20060210964 Prevention and treatment of amyloid-associated disorders |
| 09/21/2006 | US20060210656 Synergistic Effects of Nuclear Transcription Factor NF-kB Inhibitors and Anti-Neoplastic Agents |
| 09/21/2006 | US20060210647 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| 09/21/2006 | US20060210624 Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs |
| 09/21/2006 | US20060210622 Surface modified particulate compositions of biologically active substances |
| 09/21/2006 | US20060210575 Cytotoxic protein and utilization thereof |
| 09/21/2006 | US20060210565 Antagonists of HMG1 for treating inflammatory conditions |
| 09/21/2006 | US20060210552 Compositions and methods for systemic inhibition of cartilage degradation |
| 09/21/2006 | US20060210551 Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses |
| 09/21/2006 | US20060210548 Method for reducing obstructive hydrocephalus |
| 09/21/2006 | US20060210531 Agent eleveting dendritic cell precursor level in blood |
| 09/21/2006 | US20060210477 Therapeutic agent for cancer |
| 09/21/2006 | CA2601179A1 Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
| 09/21/2006 | CA2599653A1 Methods of reducing microbial contamination |
| 09/21/2006 | CA2599473A1 Antiviral compositions and methods of use |
| 09/21/2006 | CA2581402A1 Novel activating agent of glucose uptake and a screening method therefor |
| 09/20/2006 | EP1703014A1 Allergen suppressor, allergen-suppression processed fiber and method of producing the same |
| 09/20/2006 | EP1702920A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/20/2006 | EP1702627A1 Analgesic combination of sodium channel blockers with opioid antagonists |
| 09/20/2006 | EP1702626A1 Inhibitor for the formation of gammad-secretase complex |
| 09/20/2006 | EP1702625A1 Medicine containing genetically modified antibody against chemokine receptor ccr4 |
| 09/20/2006 | EP1702624A1 Immunotherapeutic stress protein-peptide complexes against cancer |
| 09/20/2006 | EP1702623A2 Use of interferon gamma for the treatment of cardiac hypertrophy |
| 09/20/2006 | EP1702515A2 Fat or oil composition |
| 09/20/2006 | EP1702064A2 A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan |
| 09/20/2006 | EP1702056A2 Non-animal product containing veterinary formulations |
| 09/20/2006 | EP1701741A2 Complexes having adjuvant activity |
| 09/20/2006 | EP1701725A1 Methods and compositions |